317 related articles for article (PubMed ID: 36601636)
1. Current state of CAR-T therapy for T-cell malignancies.
Luo L; Zhou X; Zhou L; Liang Z; Yang J; Tu S; Li Y
Ther Adv Hematol; 2022; 13():20406207221143025. PubMed ID: 36601636
[TBL] [Abstract][Full Text] [Related]
2. CAR-T Cell Therapy for T-Cell Malignancies.
Testa U; Chiusolo P; Pelosi E; Castelli G; Leone G
Mediterr J Hematol Infect Dis; 2024; 16(1):e2024031. PubMed ID: 38468828
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor T cells march into T cell malignancies.
Tang J; Zhao X
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13459-13475. PubMed ID: 37468610
[TBL] [Abstract][Full Text] [Related]
4. CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
Stem Cell Res Ther; 2021 Oct; 12(1):527. PubMed ID: 34620233
[TBL] [Abstract][Full Text] [Related]
5. Progress and Pitfalls of Chimeric Antigen Receptor T Cell Immunotherapy against T Cell Malignancies.
Angelos MG; Patel RP; Ruella M; Barta SK
Transplant Cell Ther; 2024 Feb; 30(2):171-186. PubMed ID: 37866783
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.
Polgárová K; Otáhal P; Šálek C; Pytlík R
Front Oncol; 2022; 12():876758. PubMed ID: 35600381
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.
Alcantara M; Tesio M; June CH; Houot R
Leukemia; 2018 Nov; 32(11):2307-2315. PubMed ID: 30315238
[TBL] [Abstract][Full Text] [Related]
8. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma.
Zhang M; Chen D; Fu X; Meng H; Nan F; Sun Z; Yu H; Zhang L; Li L; Li X; Wang X; Wang M; You F; Li Z; Chang Y; Zhou Z; Yan J; Li J; Wu X; Wang Y; Wang Y; Xiang S; Chen Y; Pan G; Xu H; Zhang B; Yang L
Clin Cancer Res; 2022 Jul; 28(13):2830-2843. PubMed ID: 35435984
[TBL] [Abstract][Full Text] [Related]
9. CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities.
Ren A; Tong X; Xu N; Zhang T; Zhou F; Zhu H
Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36680011
[TBL] [Abstract][Full Text] [Related]
10. CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies.
To V; Evtimov VJ; Jenkin G; Pupovac A; Trounson AO; Boyd RL
Front Immunol; 2022; 13():968395. PubMed ID: 36059451
[TBL] [Abstract][Full Text] [Related]
11. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection.
Jiang J; Chen J; Liao C; Duan Y; Wang Y; Shang K; Huang Y; Tang Y; Gao X; Gu Y; Sun J
Leukemia; 2023 Aug; 37(8):1660-1670. PubMed ID: 37391486
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T-cell therapy for T-ALL and AML.
Wei W; Yang D; Chen X; Liang D; Zou L; Zhao X
Front Oncol; 2022; 12():967754. PubMed ID: 36523990
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies.
Chen D; You F; Xiang S; Wang Y; Li Y; Meng H; An G; Zhang T; Li Z; Jiang L; Wu H; Sheng B; Zhang B; Yang L
Am J Cancer Res; 2021; 11(11):5263-5281. PubMed ID: 34873460
[TBL] [Abstract][Full Text] [Related]
14. CAR-Based Approaches to Cutaneous T-Cell Lymphoma.
Scarfò I; Frigault MJ; Maus MV
Front Oncol; 2019; 9():259. PubMed ID: 31058076
[TBL] [Abstract][Full Text] [Related]
15. Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?
Assi R; Salman H
Cells; 2022 Dec; 11(24):. PubMed ID: 36552738
[TBL] [Abstract][Full Text] [Related]
16. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
Gomes-Silva D; Srinivasan M; Sharma S; Lee CM; Wagner DL; Davis TH; Rouce RH; Bao G; Brenner MK; Mamonkin M
Blood; 2017 Jul; 130(3):285-296. PubMed ID: 28539325
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
18. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
[TBL] [Abstract][Full Text] [Related]
19. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
Shi J; Zhang Z; Cen H; Wu H; Zhang S; Liu J; Leng Y; Ren A; Liu X; Zhang Z; Tong X; Liang J; Li Z; Zhou F; Huang L; Qin Y; Yang K; Zhang T; Zhu H
J Hematol Oncol; 2021 Oct; 14(1):162. PubMed ID: 34627328
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
